GlassScriptPhysician profile
Umang S Patel
NPI 1265548077
$6,905.69
in general payments reported to CMS, 2019-2025
45 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $1,769 · 2021: $944 · 2022: $830 · 2023: $270 · 2024: $1,175 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,455.14 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Medtronic Vascular, INC. | $1,356.65 | 2020 | |
| Lilly USA, LLC | $701.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $385.86 | 2019-2025 | |
| Abbvie INC. | $356.43 | 2020-2025 | |
| Glaxosmithkline, LLC. | $312.48 | 2019-2025 | Pediarix, Bexsero |
| Janssen Pharmaceuticals, INC | $290.87 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $226.31 | 2022-2025 | |
| Novo Nordisk INC | $152.16 | 2019-2024 | Wegovy |
| Zimvie INC. | $143.36 | 2024 | |
| Amgen INC. | $139.64 | 2021-2025 | Repatha, Otezla, Prolia |
| Outset Medical INC | $138.17 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.83 | 2021-2022 | |
| Astellas Pharma US INC | $80.62 | 2020-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $74.35 | 2024-2025 | Voquezna |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umang Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.